# ZBTB16

Source: https://onco.cc/targets/zbtb16/  
OnCo record `zbtb16` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.

## Summary

Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters. May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues.

Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.98, genetic association 0.43, somatic mutation 0.84, animal model 0.64). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Oesophageal Squamous Cell Carcinoma, Prostate Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: zinc finger and BTB domain containing 16; Zinc finger and BTB domain-containing protein 16; ZNF145
- Tags: cancer-genes-wave
- Symbol: ZBTB16
- Class: transcription
- Biology: Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters. May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues. Probable substrate-recognition component of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Location: Nucleus; Nucleus, nuclear body (UniProt). Locus 11q23.2 (HGNC).
- Where found: Prostate cancer: Open Targets association 0.51 with prostate cancer (MONDO_0008315); IntOGen driver in 1 cohort (PRAD); Oesophageal cancer: IntOGen driver in 1 cohort (ESCC); Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898); Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254); Lung cancer: Open Targets association 0.52 with lung cancer (MONDO_0008903); Oesophageal squamous cell carcinoma: IntOGen driver in 1 cohort (ESCC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:12930: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12930
- UniProt Q05516: https://www.uniprot.org/uniprotkb/Q05516/entry
- NCBI Gene 7704: https://www.ncbi.nlm.nih.gov/gene/7704
- Ensembl ENSG00000109906: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109906

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Melanoma](https://onco.cc/cancers/melanoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/zbtb16.json